TRVI - Trevi Therapeutics, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
10.22 0.4 (3.91%)	---	---	---	0.0 (0.0%)	0.32 (3.11%)	0.0 (0.0%)	0.0 (0.0%)

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Category: PHARMACEUTICAL PREPARATIONS

Market Period: Closed

Earnings & Ratios

Basic EPS:: -0.09
Diluted EPS:: -0.09
Basic P/E:: -118.0
Diluted P/E:: -118.0
RSI(14) 1m:: 100.0
VWAP:: 10.62
RVol:: 0.955

Events

Period	Kind	Movement	Occurred At
1m	Price decrease 1m	10.53 -0.18 (-1.67%)	Oct 15 09:42
1m	Price decrease 1m	10.68 -0.14 (-1.32%)	Oct 15 09:38
1m	Price increase 1m	10.72 +0.21 (+1.95%)	Oct 15 09:35
10m	Price increase 10m	10.72 +0.42 (+4.08%)	Oct 15 09:35